Vitamin K and cancer

Area of Science:

• Biochemistry
• Oncology
• Nutrition Science

Background:

• Subclinical vitamin K deficiency causes impaired carboxylation of vitamin K-dependent Gla proteins.
• This deficiency can arise from poor intake, malabsorption, or drug interactions.
• Vitamin K-dependent proteins play roles beyond coagulation, including in cell growth regulation.

Purpose of the Study:

• To review the impact of different vitamin K subspecies on tumor growth.
• To explore the potential anti-tumor effects of vitamin K supplementation.
• To discuss the implications of vitamin K carboxylation inhibition (e.g., warfarin) on carcinogenesis.

Main Methods:

• Literature review of existing studies on vitamin K, Gla proteins, and cancer.
• Analysis of research on warfarin and heparin's effects on vitamin K-dependent factors in carcinogenesis.
• Examination of vitamin K's anti-inflammatory properties in relation to cancer development.

Main Results:

• Evidence suggests vitamin K subspecies may influence tumor progression.
• Warfarin and heparin, by blocking vitamin K-dependent carboxylation, have shown tumor-suppressive effects in some studies.
• Vitamin K possesses anti-inflammatory properties that may affect carcinogenesis, though data is limited.

Conclusions:

• Subclinical vitamin K deficits and their role in extrahepatic Gla protein carboxylation warrant further investigation.
• Vitamin K's potential anti-tumor effects, including those mediated by anti-inflammatory actions, require more research.
• The balance of risks and benefits of vitamin K carboxylation inhibition in cancer patients needs careful consideration.